Pfizer Drives a Hard Bargain

Who knew baby formula was so desirable in emerging markets? Pfizer (NYS: PFE) reportedly got Nestle (OTC: NSRGY) and Danone into a bidding war over its nutrition business, driving the price up to $11.85 billion.

Nestle won. Danone lost. But the losers would also seem to include Abbott Labs (NYS: ABT) and Mead Johnson Nutrition (NYS: MJN) , which will continue competing with the SMA Gold brand that now has a highly motivated owner looking for high growth to justify the high purchase price.

For Pfizer, it looks like a solid deal. We already knew the pharmaceutical giant was going to unload the nutrition business; the only question was how. An IPO like Bristol-Myers Squibb (NYS: BMY) did to divest of Mead Johnson seemed like a good option, but with multiple bidders, Pfizer appears to have made the best choice to maximize value. Nestle will be able to achieve some synergies that a stand-alone company wouldn't, which helps it justify a higher price than Pfizer would likely have gotten in an IPO.

Pfizer plans to repurchase shares or "invest in other business-development opportunities" with the proceeds of the deal, which is expected to close in the middle of next year. The math works for repurchasing shares.

Earnings before interest, tax, depreciation, and amortization for the division were reportedly about $600 million. If we apply Pfizer's tax rate of 20% of operating income, the sale would knock $480 million off its 2011 earnings -- likely substantially less, as depreciation and amortization of expenses would lower that further. To keep the same earnings per share in this worst-case scenario, Pfizer would have to repurchase 374 million shares at the current cost of $8.4 billon. It's hard to know what kind of taxes it'll have to pay on the $12 billion sale, but considering this is a worst-case scenario, it looks like the transaction will help the bottom line if Pfizer uses the proceeds to repurchase shares.

Of course, there's always the option to "invest in other business-development opportunities," which hopefully means buying biotechs or licensing drugs and not another Wyeth-sized acquisition. Pfizer's shares aren't dirt cheap at the moment, and while repurchasing shares does have the added benefit of lowering the cash required for dividends, I have to think there are biotechs out there with potential to add more to earnings in the long term than repurchasing shares.

Of course, Pfizer still has its animal health business to dispose of, so maybe there will be cash for both.

Looking for more dividend ideas? Check out the Fool's free report "Secure Your Future With 9 Rock-Solid Dividend Stocks." Just click here to get your free copy.

At the time thisarticle was published Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of Pfizer. The Motley Fool has a disclosure policy.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.